ACST Stock – (NASDAQ: ACST) is providing an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually giving an update on the use of its “at-the market” equity providing plan.
As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement a “at the market” equity offering system under which Acasti may well issue as well as sell from time to time its common shares having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares were sold at prevailing market rates averaging US$1.0747 a share. No securities were marketed throughout the facilities of the TSXV or perhaps, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333-239538) as made effective on July seven, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with the services of theirs. As a direct result of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and superb as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and often will provide the Company with more freedom in its ongoing review process to enjoy and evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids as well as bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have extensive clinical proof of safety and efficacy in lowering triglycerides in people with HTG. CaPre, or hypertriglyceridemia, an OM3 phospholipid therapeutic, was being formulated for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of this press release that are not statements of current or historical fact constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking claims include known and unknown risks, uncertainties, and other unknown variables that may cause the actual outcomes of Acasti to be materially different from historical outcomes and from any later results expressed or implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, readers are urged to consider statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward looking statements, which speak simply as of the date of this particular press release. Forward-looking statements in this press release include, but aren’t confined to, statements or information concerning Acasti’s strategy, future operations and its review of strategic alternatives.
The forward looking statements contained in this specific press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward-Looking Statements” area found in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com and also on the investor section of Acasti’s website at www.acastipharma.com. Many forward-looking statements in this press release are available as of the date of this press release.
ACST Stock – Acasti does not undertake to redesign some such forward looking statements whether as a result of information which is new, future events or perhaps otherwise, except as called for by law. The forward-looking assertions contained herein are also subject typically to assumptions and risks and uncertainties that are actually described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s newest annual report on Form 10 K and quarterly report on Form 10 Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the use